Análise da eficácia da Tirzepatida como agente terapêutico para perda de peso em pacientes com Obesidade

A obesidade e o diabetes são doenças crônicas que afetam milhões de pessoas em todo o mundo, sendo consideradas epidemias crescentes. O tratamento da obesidade envolve uma abordagem multifacetada, incluindo mudanças no estilo de vida e intervenções farmacológicas. Nesse contexto, a tirzepatida, uma terapia combinada de dois medicamentos que atuam em diferentes vias metabólicas para reduzir o apetite e promover a perda de peso em pacientes com obesidade, tem se destacado como uma opção terapêutica promissora. O objetivo deste estudo foi avaliar a eficácia e segurança da tirzepatida como agente terapêutico para perda de peso em pacientes com obesidade. Para isso, foram selecionados quatro artigos que avaliaram o uso da tirzepatida em pacientes com obesidade, publicados entre 2018 e 2023, nas bases de dados PubMed (Medline), Scientific Electronic Library Online (SciELO) e Cochrane Library. Os resultados indicam que a tirzepatida é uma terapia promissora e segura para perda de peso em pacientes com obesidade. Todos os estudos relataram perda de peso significativa em pacientes tratados com essa terapia, variando de 8,6% a 16,0% do peso corporal inicial. Além disso, a tirzepatida também apresentou efeitos benéficos em outros parâmetros metabólicos, como redução da glicemia e melhora da função hepática. Efeitos adversos foram relatados em menor frequência e gravidade em comparação com outras terapias para perda de peso. Em resumo, a tirzepatida é uma terapia combinada de dois medicamentos que tem demonstrado eficácia e segurança para a perda de peso em pacientes com obesidade, de acordo com os resultados de quatro estudos avaliados nesta pesquisa. Essa terapia pode ser uma opção terapêutica válida para pacientes com obesidade. No entanto, é importante destacar a necessidade de mais pesquisas para avaliar sua eficácia e segurança a longo prazo e sua aplicabilidade em diferentes populações. Portanto, é fundamental que o tratamento seja realizado com acompanhamento médico e que cada caso seja avaliado individualmente

Frequency of Leishmania ssp. infection among HIV-infected patients living in an urban area

Introdução: coinfecção Leishmania/HIV representa um grande problema de saúde visto que há maior recidiva e letalidade por leishmaniose visceral na população de pacientes vivendo com HIV/aids. No entanto, pouco se sabe a respeito da frequência da infecção por Leishmania em pacientes assintomáticos com HIV, que podem futuramente desenvolver doença plenamente manifesta. Ademais poucas informações sobre o desempenho dos métodos de diagnóstico laboratorial de leishmaniose em pacientes coinfectados estão disponíveis no Brasil e na América Latina. Objetivos: avaliar a frequência da infecção por Leishmania spp. em pacientes com HIV/aids em uma coorte de São Paulo/SP, a positividade dos métodos sorológicos e moleculares em pacientes com HIV/aids e as possíveis associações da positividade dos diferentes métodos laboratoriais com variáveis clínicas, laboratoriais e epidemiológicas. Material e métodos: estudo transversal, realizado com pacientes atendidos no Instituto de Infectologia Emílio Ribas com diagnóstico de infecção pelo HIV. A amostra foi calculada com base na prevalência da infecção por Leishmania spp. em pacientes com HIV/aids, estimada em estudos prévios. Foram incluídos 240 pacientes nesta amostragem, os quais foram submetidos à coleta de sangue periférico em dois tubos: um tubo seco para análise sorológica; um tubo contendo EDTA, para o diagnóstico molecular. As amostras foram submetidas aos seguintes testes diagnósticos: ELISA usando antígenos de L. major-like (ELISA L. major-like); ELISA usando antígenos de Leptomonas seymouri (ELISA Leptomonas); ELISA usando antígenos rk39 (ELISA rK39); ELISA usando antígenos rK28 (ELISA rK28); Reação de imunofluorescência indireta (RIFI); Teste de Aglutinação Direta (DAT); Reação em cadeia da polimerase (PCR) com os seguintes genes alvos: kDNA (PCR kDNA) e ITS-1 (PCR ITS-1). Resultados: a frequência, levando-se em consideração a positividade em pelo menos um dos métodos empregados, foi de 34,6%. Sessenta pacientes (25%) foram positivos para ELISA L. major-like; nove (3,8%) para ELISA Leptomonas; três (1,3%) para ELISA rK39; seis (2,5%) para ELISA rK28; onze (4,6%) para RIFI; quatro (1,7%) para PCR kDNA; 10 (4,2%) para PCR ITS-1. Nenhuma amostra foi positiva para DAT. Não houve associação da positividade dos testes com contato com área endêmica para LV ou presença de sintomas sugestivos de LV. Para ELISA L.major-like, ELISA Leptomonas e RIFI, houve associação entre valores de contagem de linfócitos T CD4+ e positividade dos testes. Conclusões: Houve uma alta prevalência da infecção por Leishmania spp. em pacientes infectados pelo HIV na amostra estudada, principalmente utilizando-se ELISA com antígeno total de L. major-like. Apesar de existir a possibilidade de reação cruzada com outros antígenos que possam ter influenciado na positividade de alguns testes, especialmente ELISA L. major-like, outros testes considerados altamente específicos para o diagnóstico de infecção por Leishmania também se apresentaram positivos, o que pode demonstra a magnitude da coinfecção Leishmania/HIV na amostra estudada. Houve associação entre positividade de alguns testes estudados e os valores de linfócitos T CD4+, com maior positividade destes testes em pacientes mais imunodeprimidos. Presença de sintomatologia ou epidemiologia para LV não tiveram influência na positividade dos testes diagnósticosIntroduction: Leishmania/HIV coinfection represents a major health problem since there is greater relapse and lethality due to visceral leishmaniasis in HIV infected population. However, there are few information about the frequency of Leishmania infection in asymptomatic HIV infected individuals, who may develop full-blown symptomatic disease in the future. In addition, few information about the performance of laboratory diagnostic methods for leishmaniasis in coinfected patients are available in Brazil and Latin America. Objectives: The main objective is evaluate the frequency of Leishmania spp. infection in HIV infected patients in a patient cohort from São Paulo/SP. This study also aims to evaluate the positivity of the serological and molecular methods in HIV/AIDS patients and the possible associations of the positivity of the different laboratory methods regarding to clinical, laboratory and epidemiological variables. Material and methods: a cross-sectional study including HIV infected patients treated at Institute of Infectious Diseases Emilio Ribas. The sample was calculated considering the frequency of Leishmania spp. infection in HIV infected patients estimated in previous studies. Two hundred and forty patients were included, whose were submitted to peripheral blood collection in two tubes: a dry tube for serological analysis; a tube containing EDTA, for molecular diagnosis. The samples were submitted to the following diagnostic tests: ELISA using L. major-like antigens (ELISA L. major-like); ELISA using Leptomonas seymouri antigens (ELISA Leptomonas); ELISA using rk39 antigens (ELISA rK39); ELISA using rK28 antigens (ELISA rK28); indirect fluorescent-antibody test (IFAT); direct agglutination test (DAT); polymerase chain reaction (PCR) with the following target genes: kDNA (kDNA PCR) and ITS-1 (ITS-1 PCR). Results: the frequency considering at least one test positive was 34.6%. Sixty patients (25%) were positive by ELISA L. major-like; nine (3.8%) by ELISA Leptomonas; three (1.3%) by ELISA rK39; six (2.5%) by ELISA rK28; eleven (4.6%) by IFAT; four (1.7%) by kDNA PCR; 10 (4.2%) by ITS-1 PCR. No sample was positive by DAT. There was no association between the positivity of the tests and history of having lived in a VL transmission area or presence of symptoms suggestive of VL. For ELISA L.major-like, ELISA Leptomonas and IFAT, there was an association between CD4+ T-lymphocyte counts and test positivity. Conclusions: there was a high prevalence of Leishmania spp. in HIV-infected patients included, mainly using ELISA with total L. major-like antigen. Although there is a possibility of cross-reaction with other antigens that can influence the positivity of some tests, especially ELISA L. major-like, other tests considered to be highly specific for the diagnosis of Leishmania infection were also positive, which may demonstrate the magnitude of Leishmania/HIV coinfection in the sample studied. There was an association between the positivity of some tests studied and the values of T CD4+ lymphocytes, with a higher positivity of these tests in more immunosuppressed patients. Presence of symptoms or epidemiology for VL had no influence on the positivity of the diagnostic test

Rhinocerebral zygomycosis in a diabetic patient

Rhinocerebral zygomycosis is the most frequent form of fungal infection caused by members of the Zygomycetes class. A fatal case of rhinocerebral zygomycosis caused by Rhizopus (oryzae) arrhizus with histopathological and mycological diagnosis is reported in a diabetic patient

Increased circulating levels of angiotensin-(1–7) in severely ill COVID-19 patients

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies

Background: Geoeconomic variations in epidemiology, the practice of ventilation, and outcome in invasively ventilated intensive care unit (ICU) patients without acute respiratory distress syndrome (ARDS) remain unexplored. In this analysis we aim to address these gaps using individual patient data of four large observational studies. Methods: In this pooled analysis we harmonised individual patient data from the ERICC, LUNG SAFE, PRoVENT, and PRoVENT-iMiC prospective observational studies, which were conducted from June, 2011, to December, 2018, in 534 ICUs in 54 countries. We used the 2016 World Bank classification to define two geoeconomic regions: middle-income countries (MICs) and high-income countries (HICs). ARDS was defined according to the Berlin criteria. Descriptive statistics were used to compare patients in MICs versus HICs. The primary outcome was the use of low tidal volume ventilation (LTVV) for the first 3 days of mechanical ventilation. Secondary outcomes were key ventilation parameters (tidal volume size, positive end-expiratory pressure, fraction of inspired oxygen, peak pressure, plateau pressure, driving pressure, and respiratory rate), patient characteristics, the risk for and actual development of acute respiratory distress syndrome after the first day of ventilation, duration of ventilation, ICU length of stay, and ICU mortality. Findings: Of the 7608 patients included in the original studies, this analysis included 3852 patients without ARDS, of whom 2345 were from MICs and 1507 were from HICs. Patients in MICs were younger, shorter and with a slightly lower body-mass index, more often had diabetes and active cancer, but less often chronic obstructive pulmonary disease and heart failure than patients from HICs. Sequential organ failure assessment scores were similar in MICs and HICs. Use of LTVV in MICs and HICs was comparable (42·4% vs 44·2%; absolute difference -1·69 [-9·58 to 6·11] p=0·67; data available in 3174 [82%] of 3852 patients). The median applied positive end expiratory pressure was lower in MICs than in HICs (5 [IQR 5-8] vs 6 [5-8] cm H2O; p=0·0011). ICU mortality was higher in MICs than in HICs (30·5% vs 19·9%; p=0·0004; adjusted effect 16·41% [95% CI 9·52-23·52]; p<0·0001) and was inversely associated with gross domestic product (adjusted odds ratio for a US$10 000 increase per capita 0·80 [95% CI 0·75-0·86]; p<0·0001). Interpretation: Despite similar disease severity and ventilation management, ICU mortality in patients without ARDS is higher in MICs than in HICs, with a strong association with country-level economic status

Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries

© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 licenseBackground: 80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on postoperative mortality. Methods: This was a multicentre, international prospective cohort study of consecutive adult patients undergoing surgery for primary breast, colorectal, or gastric cancer requiring a skin incision done under general or neuraxial anaesthesia. The primary outcome was death or major complication within 30 days of surgery. Multilevel logistic regression determined relationships within three-level nested models of patients within hospitals and countries. Hospital-level infrastructure effects were explored with three-way mediation analyses. This study was registered with ClinicalTrials.gov, NCT03471494. Findings: Between April 1, 2018, and Jan 31, 2019, we enrolled 15 958 patients from 428 hospitals in 82 countries (high income 9106 patients, 31 countries; upper-middle income 2721 patients, 23 countries; or lower-middle income 4131 patients, 28 countries). Patients in LMICs presented with more advanced disease compared with patients in high-income countries. 30-day mortality was higher for gastric cancer in low-income or lower-middle-income countries (adjusted odds ratio 3·72, 95% CI 1·70–8·16) and for colorectal cancer in low-income or lower-middle-income countries (4·59, 2·39–8·80) and upper-middle-income countries (2·06, 1·11–3·83). No difference in 30-day mortality was seen in breast cancer. The proportion of patients who died after a major complication was greatest in low-income or lower-middle-income countries (6·15, 3·26–11·59) and upper-middle-income countries (3·89, 2·08–7·29). Postoperative death after complications was partly explained by patient factors (60%) and partly by hospital or country (40%). The absence of consistently available postoperative care facilities was associated with seven to 10 more deaths per 100 major complications in LMICs. Cancer stage alone explained little of the early variation in mortality or postoperative complications. Interpretation: Higher levels of mortality after cancer surgery in LMICs was not fully explained by later presentation of disease. The capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention. Early death after cancer surgery might be reduced by policies focusing on strengthening perioperative care systems to detect and intervene in common complications. Funding: National Institute for Health Research Global Health Research Unit

Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. Methods: A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Findings: Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Interpretation: Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. Funding: National Institute for Health and Care Research

The surgical safety checklist and patient outcomes after surgery: a prospective observational cohort study, systematic review and meta-analysis

© 2017 British Journal of Anaesthesia Background: The surgical safety checklist is widely used to improve the quality of perioperative care. However, clinicians continue to debate the clinical effectiveness of this tool. Methods: Prospective analysis of data from the International Surgical Outcomes Study (ISOS), an international observational study of elective in-patient surgery, accompanied by a systematic review and meta-analysis of published literature. The exposure was surgical safety checklist use. The primary outcome was in-hospital mortality and the secondary outcome was postoperative complications. In the ISOS cohort, a multivariable multi-level generalized linear model was used to test associations. To further contextualise these findings, we included the results from the ISOS cohort in a meta-analysis. Results are reported as odds ratios (OR) with 95% confidence intervals. Results: We included 44 814 patients from 497 hospitals in 27 countries in the ISOS analysis. There were 40 245 (89.8%) patients exposed to the checklist, whilst 7508 (16.8%) sustained ≥1 postoperative complications and 207 (0.5%) died before hospital discharge. Checklist exposure was associated with reduced mortality [odds ratio (OR) 0.49 (0.32–0.77); P\u3c0.01], but no difference in complication rates [OR 1.02 (0.88–1.19); P=0.75]. In a systematic review, we screened 3732 records and identified 11 eligible studies of 453 292 patients including the ISOS cohort. Checklist exposure was associated with both reduced postoperative mortality [OR 0.75 (0.62–0.92); P\u3c0.01; I2=87%] and reduced complication rates [OR 0.73 (0.61–0.88); P\u3c0.01; I2=89%). Conclusions: Patients exposed to a surgical safety checklist experience better postoperative outcomes, but this could simply reflect wider quality of care in hospitals where checklist use is routine

Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries

This was an investigator initiated study funded by Nestle Health Sciences through an unrestricted research grant, and by a National Institute for Health Research (UK) Professorship held by RP. The study was sponsored by Queen Mary University of London